SANA BIOTECHNOLOGY INC. - COMMON STOCK

Sana Biotechnology to Host Research & Development Day

24 4 2023 16:06:02 提供 Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

19 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

13 4 2023 09:00:01 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

12 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

10 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

16 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

14 3 2023 16:53:13 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference

01 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference

02 2 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

26 1 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 1 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting

11 12 2022 17:30:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization

29 11 2022 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category

14 11 2022 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting

03 11 2022 09:07:05 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates

02 11 2022 16:05:02 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at September 2022 Investor Conferences

09 9 2022 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates

04 8 2022 16:05:01 提供 Nasdaq GlobeNewswire

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

17 6 2022 09:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting

13 6 2022 16:05:00 提供 Nasdaq GlobeNewswire